Immunogenicity and safety of concomitant and sequential administration of yellow fever YF-17D vaccine and tetravalent dengue vaccine candidate TAK-003: A phase 3 randomized, controlled study.
<h4>Background</h4>Yellow fever (YF) vaccination is often mandatory for travelers to YF-endemic areas. The areas with risk of YF partially overlap with those of dengue, for which there is currently no recommended vaccine available for dengue-naïve individuals. This phase 3 study assesse...
Na minha lista:
Main Authors: | Vianney Tricou (Author), Brandon Essink (Author), John E Ervin (Author), Mark Turner (Author), Ian Escudero (Author), Martina Rauscher (Author), Manja Brose (Author), Inge Lefevre (Author), Astrid Borkowski (Author), Derek Wallace (Author) |
---|---|
Formato: | Livro |
Publicado em: |
Public Library of Science (PLoS),
2023-03-01T00:00:00Z.
|
Assuntos: | |
Acesso em linha: | Connect to this object online. |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|
Registos relacionados
-
Immunogenicity and safety of a tetravalent dengue vaccine in dengue-naïve adolescents in Mexico City
Por: Shibadas Biswal, et al.
Publicado em: (2021) -
Defining levels of dengue virus serotype-specific neutralizing antibodies induced by a live attenuated tetravalent dengue vaccine (TAK-003).
Por: Laura J White, et al.
Publicado em: (2021) -
An open-label, Phase 3 trial of TAK-003, a live attenuated dengue tetravalent vaccine, in healthy US adults: immunogenicity and safety when administered during the second half of a 24-month shelf-life
Por: Sanjay S. Patel, et al.
Publicado em: (2023) -
Absence of transmission of vYF next generation Yellow Fever vaccine in mosquitoes.
Por: Rachel Bellone, et al.
Publicado em: (2022) -
In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination.
Por: Stephen S Whitehead, et al.
Publicado em: (2017)